Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Health Econ. 2005 Jun;6(2):159-65.

Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model.

Author information

  • 1Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, Ottawa, ONT, Canada. susie_elsaadany@hc-sc.gc.ca

Abstract

This Canadian hepatitis C model estimates economic burden of disease using Markov modeling to predict progression over 11 health states annually from 2001 to 2040. Incidence-based estimates help demonstrate the capability to determine cost-effectiveness of programs to prevent different proportions of incident cases. Benefits of prevention increase linearly with the number of incident cases prevented. The model forecasts annual health care costs for the treatment of HCV-related disease ranging from $103 to $158 million over time. Health care costs attributable to 2001 incidence cohort are forecast at $14.6 million for prevention. The increasing cost of HCV provides a framework for further analysis and implementation of long-term policies aimed at appropriate allocation of resources for health in Canada.

PMID:
15761777
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk